

2018 Primary biliary cholangitis Drug Development-Pipeline Analysis Report

<https://marketpublishers.com/r/2F59BF31F68EN.html>

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 2F59BF31F68EN

Abstracts

Primary biliary cholangitis (PBC) is a long term chronic and autoimmune disease in which the bile ducts are inflamed and gradually destroyed. This results in built of bile in the liver, resulting in damage to the liver. The rare disease has limited treatment options with FDA approving obeticholic acid plus ursodeoxycholic acid as a single therapy.

Over 25 companies and universities are focusing on developing treatment options for Primary biliary cholangitis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Primary biliary cholangitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Primary biliary cholangitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Primary biliary cholangitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

2 PRIMARY BILLARY CHOLANGITIS (PBC) PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Primary billary cholangitis (PBC) Pipeline Snapshot

2.3 Primary billary cholangitis (PBC) Pipeline by Phase

2.4 Primary billary cholangitis (PBC) Pipeline by Company

2.5 Primary billary cholangitis (PBC) Pipeline by Mechanism of Action

3 PRIMARY BILLARY CHOLANGITIS (PBC)- COMPANY WISE PIPELINE ANALYSIS

Albireo AB

Arena Pharmaceuticals

CymaBay Therapeutics

Enanta Pharmaceuticals

FF Pharma

Genfit

Genkyotex

GlaxoSmithKline

Intercept Pharmaceuticals

KAN Research Institute

NGM Biopharmaceuticals

Novartis

Phenex Pharmaceuticals

Retrophin

Suzhou Zelgen Biopharmaceutical Co Ltd

Tiziana Life Sciences

Virobay Inc

Zydus Cadila

4 PRIMARY BILLARY CHOLANGITIS (PBC) R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN PRIMARY BILLARY CHOLANGITIS (PBC) PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Primary biliary cholangitis (PBC) Pipeline by Phase, H1- 2018

Figure 2: Primary biliary cholangitis (PBC) Pipeline by Companies, H1- 2018

Figure 3: Company Wise Pipeline Drug Phases, H1- 2018

Figure 4: Primary biliary cholangitis (PBC) Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Primary biliary cholangitis (PBC) Pipeline by Phase, H1- 2018

Table 2: Primary biliary cholangitis (PBC) Pipeline by Companies, H1- 2018

Table 3: Primary biliary cholangitis (PBC) Pipeline by Mechanism of Action, H1- 2018

Table 4: Albireo AB Primary biliary cholangitis Pipeline, May 2018

Table 5: Arena Pharmaceuticals Primary biliary cholangitis Pipeline, May 2018

Table 6: CymaBay Therapeutics Primary biliary cholangitis Pipeline, May 2018

Table 7: Enanta Pharmaceuticals Primary biliary cholangitis Pipeline, May 2018

Table 8: FF Pharma Primary biliary cholangitis Pipeline, May 2018

Table 9: Genfit Primary biliary cholangitis Pipeline, May 2018

Table 10: Genkyotex Primary biliary cholangitis Pipeline, May 2018

Table 11: GlaxoSmithKline Primary biliary cholangitis Pipeline, May 2018

Table 12: Intercept Pharmaceuticals Primary biliary cholangitis Pipeline, May 2018

Table 13: KAN Research Institute Primary biliary cholangitis Pipeline, May 2018

Table 14: NGM Biopharmaceuticals Primary biliary cholangitis Pipeline, May 2018

Table 15: Novartis Primary biliary cholangitis Pipeline, May 2018

Table 16: Phenex Pharmaceuticals Primary biliary cholangitis Pipeline, May 2018

Table 17: Retrophin Primary biliary cholangitis Pipeline, May 2018

Table 18: Suzhou Zelgen Biopharmaceutical Co Ltd Primary biliary cholangitis Pipeline, May 2018

Table 19: Tiziana Life Sciences Primary biliary cholangitis Pipeline, May 2018

Table 20: Virobay Inc Primary biliary cholangitis Pipeline, May 2018

Table 21: Zydus Cadila Primary biliary cholangitis Pipeline, May 2018

I would like to order

Product name: 2018 Primary biliary cholangitis Drug Development- Pipeline Analysis Report

Product link: <https://marketpublishers.com/r/2F59BF31F68EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2F59BF31F68EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970